Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $145 to $150. This adjustment reflects a positive outlook on the company's stock.
January 23, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Neurocrine Biosciences and raises the price target to $150, indicating a bullish outlook.
The increase in price target by a reputable analyst like Carter Gould from Barclays can lead to increased investor confidence and a potential short-term rise in the stock price of Neurocrine Biosciences. Analyst ratings and price target adjustments are closely watched by investors as they often reflect the expected performance and valuation of a company based on thorough research and analysis.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100